Athersys, Inc (ATHX)

Etorro trading 970x250
Athersys, Inc (ATHX) Logo

About Athersys, Inc

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Address: 3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

Athersys, Inc News and around…

Latest news about Athersys, Inc (ATHX) common stock and company :

Notable Monday Option Activity: ATHX, ZG, SHAK
18 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Athersys Inc (ATHX), where a total of 5,846 contracts have traded so far, representing approximately 584,600 underlying shares. That amounts to about 65.2% of ATHX's average daily trading volume over the past month of 896,775 shares..

Athersys to Host Third Quarter Financial Results Call
18 Oct, 2021 FinancialContent

Athersys to Host Q3 Financial Results Call on November 15, 2021 at 4:30 pm ET.

First Week of ATHX December 17th Options Trading
15 Oct, 2021 FinancialContent

Investors in Athersys Inc (ATHX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATHX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference
28 Sep, 2021 FinancialContent

Athersys, a late-stage clinical company developing MultiStem cell therapy, will be participating in two events at the Cell & Gene Meeting on the Mesa.

Athersys (NASDAQ:ATHX) shareholders have endured a 34% loss from investing in the stock three years ago
24 Sep, 2021 Yahoo! Finance

Many investors define successful investing as beating the market average over the long term. But the risk of stock...

Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?
22 Sep, 2021 Yahoo! Finance

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Interesting ATHX Call Options For January 2024
15 Sep, 2021 FinancialContent

Investors in Athersys Inc (ATHX) saw new options begin trading this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Notable Tuesday Option Activity: ELS, ATHX, REKR
31 Aug, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Equity Lifestyle Properties Inc (ELS), where a total of 1,945 contracts have traded so far, representing approximately 194,500 underlying shares. That amounts to about 42% of ELS's average daily trading volume over the past month of 463,555 shares..

Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
16 Aug, 2021 Yahoo! Finance

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients
13 Aug, 2021 FinancialContent
Notable Tuesday Option Activity: CLF, ATHX, BRSP
10 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cleveland-Cliffs Inc (CLF), where a total volume of 242,343 contracts has been traded thus far today, a contract volume which is representative of approximately 24.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 93.6% of CLF's average daily trading volume over the past month, of 25.9 million shares..

Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
10 Aug, 2021 FinancialContent

Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.

Athersys (ATHX) Q2 2021 Earnings Call Transcript
10 Aug, 2021 FinancialContent

ATHX earnings call for the period ending June 30, 2021.

Athersys: Q2 Earnings Insights
09 Aug, 2021 FinancialContent

Shares of Athersys (NASDAQ:ATHX) increasedin after-market trading after the company reported Q2 results. Quarterly ...

Athersys Reports Second Quarter 2021 Results
09 Aug, 2021 FinancialContent

Athersys reports Q2 earnings and positive topline ARDS data evaluating MultiStem® from its partner HEALIOS, K.K. The companies advance partnership.

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

12 Health Care Stocks Moving In Friday's After-Market Session
06 Aug, 2021 FinancialContent

Gainers Nuwellis (NASDAQ:NUWE) shares increased by 5.63% to $4.5 during Friday's after-market session. The market value of their ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
06 Aug, 2021 FinancialContent

Gainers Applied Molecular (NASDAQ:AMTI) shares increased by 19.38% to $35.54 during Friday's pre-market session. The ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Athersys Stock Rises on Positive Results for Stem Cell Therapy
06 Aug, 2021 Yahoo! Finance

Athersys partner Healios releases positive results from a trial of its MultiStem cell therapy (invimestrocel) for acute respiratory distress syndrome.

Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study
06 Aug, 2021 FinancialContent

Healios announces positive topline clinical data from the ONE-BRIDGE study evaluating MultiStem for acute respiratory distress syndrome (ARDS).

Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership
05 Aug, 2021 FinancialContent

Healios and Athersys deepen their partnership and improve the collaboration agreement to enhance preparations for commercial activity in Japan.

Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
29 Jul, 2021 Yahoo! Finance

Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASDAQ: PSTI) are among others that understand the importance of creating new, effective pharmaceutical critical care products for unmet needs—especially in a post-pandemic world. Among the most vulnerable patients in the COVID-19 pandemic were undoubtedly elderly sufferers, whose multiple risk factors

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Athersys to Host Second Quarter Financial Results Call
13 Jul, 2021 FinancialContent

Athersys to Host Second Quarter Financial Results Call on August 9th, 2021.

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
01 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Athersys, Inc (ATHX) is a NASDAQ Common Stock listed in , ,

970x250